ALSO NOTED: Alizyme strikes Phase III accord; Nymox touting lead candidate; Daiichi transfers Plavix rights; and much more...

> Alizyme has reached an agreement with the FDA under the Special Protocol Assessment procedure for the design of a pivotal Phase III clinical trial for renzapride in constipation-predominant irritable bowel syndrome. Release

> Nymox Pharmaceutical is touting Phase I-II trial results for NX-1207, saying that its lead drug candidate is showing promise as a treatment for benign prostatic hyperplasia. Patients in the trials demonstrated a "statistically significant shrinkage in prostate size." A large Phase II trial is scheduled to wrap up later this year. Release

> Daiichi Pharmaceutical is transferring the commercial rights to Plavix to Sanofi-Aventis Japan. Release

> Allied Capital is investing $77 million into Triax Holdings to fund its acquisition of Spear Dermatology Products and Spear Pharmaceuticals. Release

> PTC Therapeutics has won an orphan drug designation for PTC124, an experimental therapy for Duchenne muscular dystrophy and cystic fibrosis. Release

> Novartis' $20 million licensing deal with San Diego-based Anadys is a go. Release

And Finally... After the first obesity lawsuit was filed against McDonald's three years ago, the food industry has been on the offensive, erecting new laws that forbid consumers from blaming their products for any health problems that may arise. Article

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.